Screener
Cullinan Therapeutics, Inc. CGEM Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336717
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total operating expenses | 57,254 | 75,798 | 110,951 | 130,794 |
| Loss from operations | (57,254) | (75,798) | (110,951) | (130,794) |
| Other income (expense): | ||||
| Interest income | 3,648 | 5,924 | 7,746 | 12,504 |
| Other expense, net | (98) | (181) | (160) | (266) |
| Total other income | 3,550 | 5,743 | 7,586 | 12,238 |
| Net loss | $(53,704) | $(70,055) | $(103,365) | $(118,556) |
| Comprehensive income (loss): |
Item 1. Financial Statements.
FAQ
- What is Cullinan Therapeutics, Inc.'s interest income?
- Cullinan Therapeutics, Inc. (CGEM) reported interest income of $3.65M in Q2 2026.
- How has Cullinan Therapeutics, Inc.'s interest income changed year-over-year?
- Cullinan Therapeutics, Inc.'s interest income decreased by 38.4% year-over-year, from $5.92M to $3.65M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s interest income?
- Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s interest income has grown at a 161.2% compound annual growth rate (CAGR), from $477K to $22.21M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Cullinan Therapeutics, Inc.'s interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude